Anticancer agents cardiovascular toxicities

Cardiovascular toxicities have been observed in patients with a number of anticancer agents. These toxicities have included hypertension, cardiomyopathy, left ventricular dysfunction, congestive heart failure, infarction, and thrombosis. In most cases, the standard repeated-dose toxicology studies conducted in normal animals have failed to predict these clinical toxicities. One reason may be that other comorbidities need to be present before the treatment-related cardiovascular... 

The small molecule anticancer agents are too numerous to describe individually in this chapter, but some representative molecules or classes are listed in Tables 1 and 2, and a few examples of those that have been associated with cardiovascular toxicity or other relevant target organ toxicities are described below. 

Table 1 Non-antibody anticancer agents associated with cardiovascular toxicities...

In summary, anticancer agents are associated with a number of toxicities including cardiovascular toxicity. The safety pharmacology studies conducted in normal animals are able to detect the potential to increase QT Interval but have not been able to identify some of the other toxicities that develop with prolonged use or in the... 

---